A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer

Christopher G. Willett, Dan G. Duda, Marek Ancukiewicz, Mira Shah, Brian G. Czito, Rex Bentley, Martin Poleski, Hiroshi Fujita, Gregory Y. Lauwers, Madeline Carroll, Douglas Tyler, Christopher Mantyh, Paul Shellito, Daniel C. Chung, Jeffrey W. Clark, Rakesh K. Jain

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Introduction. Bevacizumab is increasingly being tested with neoadjuvant regimens in patients with localized cancer, but its effects on metastasis and survival remain unknown. This study examines the long-term outcome of clinical stage II/III rectal cancer patients treated in a prospective phase II study of bevacizumab with chemoradiation and surgery. As a benchmark, we used data from an analysis of 42 patients with locally advanced rectal cancer treated with a contemporary approach of preoperative fluoropyrimidine-based radiation therapy. Materials and Methods. Outcome analyses were performed on 32 patients treated prospectively with neoadjuvant bevacizumab, 5-fluorouracil, radiation therapy, and surgery as well as 42 patients treated with standard fluoropyrimidine-based chemoradiation. Results. Overall survival, disease-free survival, and local control showed favorable trends in patients treated with bevacizumab with chemoradiation followed by surgery. Acute and postoperative toxicity appeared acceptable.

Original languageEnglish (US)
Pages (from-to)845-851
Number of pages7
JournalOncologist
Volume15
Issue number8
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Rectal Neoplasms
Survival Analysis
Safety
Radiotherapy
Benchmarking
Survival
Fluorouracil
Disease-Free Survival
Bevacizumab
Neoplasm Metastasis
Neoplasms

Keywords

  • Bevacizumab
  • Chemoradiation
  • Neoadjuvant
  • Rectal cancer
  • Toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. / Willett, Christopher G.; Duda, Dan G.; Ancukiewicz, Marek; Shah, Mira; Czito, Brian G.; Bentley, Rex; Poleski, Martin; Fujita, Hiroshi; Lauwers, Gregory Y.; Carroll, Madeline; Tyler, Douglas; Mantyh, Christopher; Shellito, Paul; Chung, Daniel C.; Clark, Jeffrey W.; Jain, Rakesh K.

In: Oncologist, Vol. 15, No. 8, 2010, p. 845-851.

Research output: Contribution to journalArticle

Willett, CG, Duda, DG, Ancukiewicz, M, Shah, M, Czito, BG, Bentley, R, Poleski, M, Fujita, H, Lauwers, GY, Carroll, M, Tyler, D, Mantyh, C, Shellito, P, Chung, DC, Clark, JW & Jain, RK 2010, 'A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer', Oncologist, vol. 15, no. 8, pp. 845-851. https://doi.org/10.1634/theoncologist.2010-0030
Willett, Christopher G. ; Duda, Dan G. ; Ancukiewicz, Marek ; Shah, Mira ; Czito, Brian G. ; Bentley, Rex ; Poleski, Martin ; Fujita, Hiroshi ; Lauwers, Gregory Y. ; Carroll, Madeline ; Tyler, Douglas ; Mantyh, Christopher ; Shellito, Paul ; Chung, Daniel C. ; Clark, Jeffrey W. ; Jain, Rakesh K. / A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. In: Oncologist. 2010 ; Vol. 15, No. 8. pp. 845-851.
@article{66728983e9904b59a8df67ece6de5ee8,
title = "A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer",
abstract = "Introduction. Bevacizumab is increasingly being tested with neoadjuvant regimens in patients with localized cancer, but its effects on metastasis and survival remain unknown. This study examines the long-term outcome of clinical stage II/III rectal cancer patients treated in a prospective phase II study of bevacizumab with chemoradiation and surgery. As a benchmark, we used data from an analysis of 42 patients with locally advanced rectal cancer treated with a contemporary approach of preoperative fluoropyrimidine-based radiation therapy. Materials and Methods. Outcome analyses were performed on 32 patients treated prospectively with neoadjuvant bevacizumab, 5-fluorouracil, radiation therapy, and surgery as well as 42 patients treated with standard fluoropyrimidine-based chemoradiation. Results. Overall survival, disease-free survival, and local control showed favorable trends in patients treated with bevacizumab with chemoradiation followed by surgery. Acute and postoperative toxicity appeared acceptable.",
keywords = "Bevacizumab, Chemoradiation, Neoadjuvant, Rectal cancer, Toxicity",
author = "Willett, {Christopher G.} and Duda, {Dan G.} and Marek Ancukiewicz and Mira Shah and Czito, {Brian G.} and Rex Bentley and Martin Poleski and Hiroshi Fujita and Lauwers, {Gregory Y.} and Madeline Carroll and Douglas Tyler and Christopher Mantyh and Paul Shellito and Chung, {Daniel C.} and Clark, {Jeffrey W.} and Jain, {Rakesh K.}",
year = "2010",
doi = "10.1634/theoncologist.2010-0030",
language = "English (US)",
volume = "15",
pages = "845--851",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "8",

}

TY - JOUR

T1 - A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer

AU - Willett, Christopher G.

AU - Duda, Dan G.

AU - Ancukiewicz, Marek

AU - Shah, Mira

AU - Czito, Brian G.

AU - Bentley, Rex

AU - Poleski, Martin

AU - Fujita, Hiroshi

AU - Lauwers, Gregory Y.

AU - Carroll, Madeline

AU - Tyler, Douglas

AU - Mantyh, Christopher

AU - Shellito, Paul

AU - Chung, Daniel C.

AU - Clark, Jeffrey W.

AU - Jain, Rakesh K.

PY - 2010

Y1 - 2010

N2 - Introduction. Bevacizumab is increasingly being tested with neoadjuvant regimens in patients with localized cancer, but its effects on metastasis and survival remain unknown. This study examines the long-term outcome of clinical stage II/III rectal cancer patients treated in a prospective phase II study of bevacizumab with chemoradiation and surgery. As a benchmark, we used data from an analysis of 42 patients with locally advanced rectal cancer treated with a contemporary approach of preoperative fluoropyrimidine-based radiation therapy. Materials and Methods. Outcome analyses were performed on 32 patients treated prospectively with neoadjuvant bevacizumab, 5-fluorouracil, radiation therapy, and surgery as well as 42 patients treated with standard fluoropyrimidine-based chemoradiation. Results. Overall survival, disease-free survival, and local control showed favorable trends in patients treated with bevacizumab with chemoradiation followed by surgery. Acute and postoperative toxicity appeared acceptable.

AB - Introduction. Bevacizumab is increasingly being tested with neoadjuvant regimens in patients with localized cancer, but its effects on metastasis and survival remain unknown. This study examines the long-term outcome of clinical stage II/III rectal cancer patients treated in a prospective phase II study of bevacizumab with chemoradiation and surgery. As a benchmark, we used data from an analysis of 42 patients with locally advanced rectal cancer treated with a contemporary approach of preoperative fluoropyrimidine-based radiation therapy. Materials and Methods. Outcome analyses were performed on 32 patients treated prospectively with neoadjuvant bevacizumab, 5-fluorouracil, radiation therapy, and surgery as well as 42 patients treated with standard fluoropyrimidine-based chemoradiation. Results. Overall survival, disease-free survival, and local control showed favorable trends in patients treated with bevacizumab with chemoradiation followed by surgery. Acute and postoperative toxicity appeared acceptable.

KW - Bevacizumab

KW - Chemoradiation

KW - Neoadjuvant

KW - Rectal cancer

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=77955042029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955042029&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2010-0030

DO - 10.1634/theoncologist.2010-0030

M3 - Article

VL - 15

SP - 845

EP - 851

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 8

ER -